跳至主要内容
临床试验/ISRCTN16325499
ISRCTN16325499进行中(未招募)未知

The safety and efficacy of focal high-dose-rate brachytherapy in the treatment of patients diagnosed with low or favorable – intermediate-risk prostate cancer and compared with low-dose-rate brachytherapy and active surveillance

ational Cancer Institute0 个研究点目标入组 150 人开始时间: 2022年11月29日最近更新:
适应症

试验速览

阶段
未知
状态
进行中(未招募)
发起方
入组人数
150

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
Male

入选标准

  • 1. Aged 40 to 75 years old
  • 2. Multiparametric magnetic resonance tomography (mpMRI) was performed, and the tumor was verified by transrectal ultrasound (TRUS) – mpMRI fusion guided biopsy together with systemic biopsy
  • 3. Histologically confirmed low- or favorable intermediate-risk PCa from mpMRI visible lesions only that meet the following criteria and there is no disease found in systemic biopsy (PSA = 10 ng/ml; ISUP = 2; T1 – T2b)
  • 4. Less than 25 % of biopsies were affected
  • 5. The size of the prostate does not exceed 60 cm3
  • 6. Index lesion is larger than 0.5 cm3 or 6 mm in diameter
  • 7. IPSS score is not greater than 18 points
  • 8. Agrees to participate in the study and signs the consent form

排除标准

  • 1. Previous radical prostate cancer treatment
  • 2. Proven extracapsular extension of disease
  • 3. Metastatic tumors

研究者

发起方
ational Cancer Institute

相似试验